Target intelligence / Profile preview

Group A Streptococcus M protein N-terminal region (M protein HVR)

Target
M protein HVR
Molecular classification
Surface protein, Virulence factor, Coiled-coil protein
01

Overview

The Group A Streptococcus (GAS) M protein is the primary surface-anchored virulence factor of Streptococcus pyogenes (UniProt, 2024). The N-terminal region of this protein is highly hypervariable and defines the emm type of the strain, serving as the primary target for protective, type-specific antibodies (Smeesters, P. R., et al., 2010). Biologically, the N-terminus facilitates immune evasion by binding host proteins such as fibrinogen and complement regulators like Factor H, which inhibits opsonophagocytosis (Cunningham, M. W., 2000). Because it is a potent immunogen, it is a central focus for vaccine development, including multivalent candidates like StreptAnova (Dale, J. B., et al., 2016). However, a significant challenge in targeting this region is its potential for molecular mimicry with human tissue proteins, which can trigger autoimmune sequelae such as rheumatic heart disease (Cunningham, M. W., 2000). Current therapeutic strategies aim to overcome this by using complex mixtures of N-terminal peptides to provide broad coverage across the numerous GAS serotypes (Dale, J. B., et al., 2016).

Other names
Emm protein hypervariable regionStreptococcus pyogenes M protein N-terminusGAS M protein HVRM protein type-specific antigen
02

Mechanism of action

Induction of type-specific opsonophagocytic antibodies that neutralize the bacteria and prevent host cell colonization by targeting the hypervariable N-terminal epitopes.

03

Biological functions

Immune evasionCell adhesionAntiphagocytic activityComplement inhibitionImmune response
04

Disease associations

InfectionRheumatic heart diseasePost-streptococcal glomerulonephritisNecrotizing fasciitisPharyngitisToxic shock syndrome
05

Safety considerations

Molecular mimicry leading to autoimmune rheumatic heart diseaseSerotype-specific immunity limiting broad protectionPotential for strain replacement
06

Interacting drugs

StreptAnova (26-valent vaccine)

2 more in the full profile.

07

Biomarkers

Anti-M protein antibody titeremm genotypeOpsonophagocytic assay (OPA) titers

Beyond the preview

Go deeper on Group A Streptococcus M protein N-terminal region (M protein HVR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Group A Streptococcus M protein N-terminal region (M protein HVR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call